In Vitro Umbilical Cord Blood Expansion Resulting in Unique CD34Bright Cell Population That Engrafts in NOD/SCID Mice
R Xu,K DeLuca,W Porter,L Garretson,J Rowley,A Liebmann-Vinson
DOI: https://doi.org/10.1016/j.bbmt.2004.12.206
2005-01-01
Biology of Blood and Marrow Transplantation
Abstract:Umbilical cord blood (UCB) has gained recognition as a viable alternative to bone marrow or mobilized peripheral blood for hematopoietic stem cell transplantation and is being used for treatment of mainly pediatric patients with various malignant or genetic blood disorders. The limited number of cells contained in a single cord blood unit remains the major bottleneck for broader application of this treatment in adult patients. Extensive research is being focused on strategies for overcoming this bottleneck. Expansion of cells from a single cord blood unit or combining 2 cord blood units for a single transplantation are the 2 most common strategies currently in clinical evaluation.Our research effort is focused on the expansion of umbilical cord blood cells. At BD Technologies, we have developed a unique higher-throughput technology platform that we have used successfully to identify a serum-free in vitro culture condition that supports expansion of UCB-derived cells. Expansion of UCB cells in this condition results in a unique cell population, characterized by a high level of glycoprotein CD34 expression. Characterization of this expanded population using flow cytometry, colony-forming assays, and gene array analysis indicate that this expanded cell population contains more primitive stem/progenitor cells than the remainder of the CD34+ population after expansion. When transplanted into sublethally irradiated NOD/SCID mice, these cells were found to engraft in the bone marrow and to develop CD19+ B-cell, CD33+ myeloid, CD34+ stem and progenitor, CD14+ monocyte, and CD42+ megakaryocyte lineages. Secondary transplantation studies indicate the long-term engraftment potential of the expanded cells.In addition, when transplanted subcutaneously on porous polymer carriers into NOD/SCID mice, the expanded cord blood cells are found to initiate neovascularization within the carrier. Immunohistochemistry revealed that human cord blood cells were incorporated into the new vasculature. We conclude that our culture condition supports expansion of UCB cells that may have relevance for therapeutic applications in humans. Umbilical cord blood (UCB) has gained recognition as a viable alternative to bone marrow or mobilized peripheral blood for hematopoietic stem cell transplantation and is being used for treatment of mainly pediatric patients with various malignant or genetic blood disorders. The limited number of cells contained in a single cord blood unit remains the major bottleneck for broader application of this treatment in adult patients. Extensive research is being focused on strategies for overcoming this bottleneck. Expansion of cells from a single cord blood unit or combining 2 cord blood units for a single transplantation are the 2 most common strategies currently in clinical evaluation. Our research effort is focused on the expansion of umbilical cord blood cells. At BD Technologies, we have developed a unique higher-throughput technology platform that we have used successfully to identify a serum-free in vitro culture condition that supports expansion of UCB-derived cells. Expansion of UCB cells in this condition results in a unique cell population, characterized by a high level of glycoprotein CD34 expression. Characterization of this expanded population using flow cytometry, colony-forming assays, and gene array analysis indicate that this expanded cell population contains more primitive stem/progenitor cells than the remainder of the CD34+ population after expansion. When transplanted into sublethally irradiated NOD/SCID mice, these cells were found to engraft in the bone marrow and to develop CD19+ B-cell, CD33+ myeloid, CD34+ stem and progenitor, CD14+ monocyte, and CD42+ megakaryocyte lineages. Secondary transplantation studies indicate the long-term engraftment potential of the expanded cells. In addition, when transplanted subcutaneously on porous polymer carriers into NOD/SCID mice, the expanded cord blood cells are found to initiate neovascularization within the carrier. Immunohistochemistry revealed that human cord blood cells were incorporated into the new vasculature. We conclude that our culture condition supports expansion of UCB cells that may have relevance for therapeutic applications in humans.